Physician profile
Patrick S Kulubya
NPI 1720057714
$2,590.68
in general payments reported to CMS, 2019-2025
18 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.54 · 2022: $243 · 2023: $404 · 2024: $514 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.10 |
| Education | $111.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $819.20 | 2022-2025 | Veltassa, Korsuva |
| Lilly USA, LLC | $311.55 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $261.93 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $210.78 | 2024-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $188.17 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $186.58 | 2024-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $159.62 | 2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $100.05 | 2024-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $86.38 | 2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $50.93 | 2024-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $48.38 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.38 | 2025 | Jardiance |
| Novo Nordisk INC | $25.49 | 2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $24.59 | 2025 | |
| Opko Pharmaceuticals, LLC | $22.50 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $20.73 | 2025 | Defencath |
| Nxstage Medical, INC. | $19.94 | 2025 | Nxstage System One, Liberty Select Cycler |
| Amgen INC. | $18.48 | 2023 | Tavneos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Kulubya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.